NVSNovartis PharmaceuticalsRunning, no new patients
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Melanoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 134 (final count)
- Started
- Oct 30, 2020
- Main results expected
- Feb 2, 2027
- Fully finished
- Feb 2, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate
Measured over: 35 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04417621 · record last updated 2026-03-12 · checked 2026-11-09 15:47 UTC